Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a Healthcare company (Biotechnology) with a market capitalization of $258M. The Maz Rating grades it against the other companies in its sector.
Allogene Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.74, Allogene Therapeutics, Inc. trades at 55.3x sales and 0.7x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $219M. It runs an operating margin of -4099.3% and a net margin of -3760.0%. It shows return on equity of -49.8%, return on invested capital of -40.2% and a free cash flow yield of -42.3%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 7.79. Over the past 52 weeks the share price ranged from $0.74 to $4.46, with a beta of 0.48.
Allogene Therapeutics, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 19 Buy, 10 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Allogene Therapeutics, Inc. (ALLO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 76.8% / 30% · Interest income / Revenue 487900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 57.9% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 487900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 57.9% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 487900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.45% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 61.0% / 33.33% · Receivables / Avg Assets (4Q) 0.15% / 33.33% · Interest income / Revenue 487900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 57.3% / 33.33% · (Cash+Recv) / Total Assets 57.3% / 33.33% · Interest income / Revenue 487900000.0% / 5% | Fail |
No. As of September 2026, Allogene Therapeutics, Inc. (ALLO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Allogene Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 487900000.0% of each dividend: Allogene Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.